文献速递胸部肿瘤

Aumolertinib用于奥希替尼不耐受NSCLC的转换治疗:ACTIVE试验

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial.
PubMed 文献 · J Thorac Oncol · 2026-06-24

ACTIVE是一项前瞻性、多中心、单臂II期试验,纳入40例奥希替尼不耐受的EGFR突变晚期NSCLC患者,在不良事件恢复至≤1级后接受aumolertinib 110 mg每日一次治疗。主要终点3个月转换成功率为70.6%(95%CI 52.5-84.9),中位转换后PFS为11.6个月,3年转换后OS率为52.4%,治疗相关AE发生率69.2%(≥3级15.4%),无aumolertinib停药或死亡。

要点

  • 奥希替尼不耐受的EGFR突变晚期NSCLC换用aumolertinib,3个月转换成功率达70.6%。
  • 转换后中位PFS为11.6个月,3年OS率52.4%,显示持续疗效。
  • 治疗相关AE发生率69.2%,≥3级15.4%,无因aumolertinib停药或死亡。

核心结论

  • 对奥希替尼不耐受的EGFR突变晚期NSCLC患者,换用aumolertinib可获得持续疗效且安全性可控,支持毒性驱动的EGFR-TKI转换作为可行临床策略。

研究设计与样本

  • 前瞻性、多中心、单臂II期试验(NCT04882345),纳入40例奥希替尼不耐受的EGFR突变晚期NSCLC患者,39例接受aumolertinib 110 mg每日一次治疗,34例可评估主要终点。

主要发现

  • 可评估人群中3个月转换成功率为70.6%(95%CI 52.5-84.9),非血液学毒性亚组为78.9%,血液学毒性亚组为60.0%。
  • 转换后中位无进展生存期为11.6个月,转换后3年总生存率为52.4%。
  • 治疗相关不良事件发生率为69.2%,≥3级为15.4%,无aumolertinib停药或死亡。

关键数值与推荐

  • 奥希替尼不耐受定义为发生≥2级血液学毒性、ALT或AST升高,或≥3级非血液学不良事件(除外ALT或AST升高)。
  • 不良事件恢复至≤1级后开始aumolertinib 110 mg每日一次。
  • 主要终点3个月转换成功定义为无疾病进展、无≥2级血液学毒性或ALT/AST升高、无≥3级非血液学不良事件。

临床怎么用

  • 对于奥希替尼因毒性不耐受的EGFR突变晚期NSCLC患者,可考虑在毒性恢复后换用aumolertinib 110 mg每日一次。
  • 换药后需监测血液学毒性及肝酶,非血液学毒性亚组转换成功率数值上更高。

局限性

  • 单臂设计,无对照人群,样本量较小(40例入组,34例可评估主要终点)。
  • 随访时间及亚组分析样本量有限,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Third-generation EGFR- tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for EGFR-mutant advanced NSCLC. Prospective data on toxicity-driven switching to alternative third-generation TKIs for intolerant patients remain limited. METHODS: In this prospective, multicenter, single-arm phase II trial (NCT04882345), patients with EGFR-mutant advanced NSCLC who developed grade 2 or higher hematologic toxicities or increase in alanine transaminase (ALT) or aspartate transaminase (AST), or grade 3 or higher nonhematologic adverse events (AEs) (excluding ALT or AST increase) on osimertinib received aumolertinib 110 mg once daily after AEs recovered to grade 1 or lower. The primary end point was the 3-month conversion success rate (absence of disease progression, grade ≥2 hematologic AEs or increase in ALT or AST, and grade ≥3 nonhematologic AEs). RESULTS: Of the 40 enrolled patients, 39 received aumolertinib, and 34 were evaluable for the primary end point. The 3-month conversion success rate was 70.6% (95% confidence interval: 52.5-84.9) in the evaluable population, with 78.9% in nonhematologic toxicity and 60.0% in hematologic toxicity subgroups. Median postswitch progression-free survival was 11.6 months, and the 3-year postswitch overall survival rate was 52.4%. Treatment-related AEs occurred in 69.2% of patients (grade ≥3: 15.4%), with no aumolertinib discontinuation or death. CONCLUSIONS: This prospective trial suggests that switching to aumolertinib achieves sustained efficacy and manageable safety in osimertinib-intolerant EGFR-mutant advanced NSCLC, supporting toxicity-driven EGFR-TKI switching as a feasible clinical strategy.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Li Z, Yao B, Huang C, et al. Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial. J Thorac Oncol. 2026. PMID: 42341878. doi:10.1016/j.jtho.2026.104062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。